Grifols, S.A. (GIFOF) Research

Grifols, S.A. is a Barcelona, Spain-based pharmaceutical company founded in 1940. The company primarily specializes in the acquisition, production, and distribution of therapeutic solutions, with a significant emphasis on products derived from human plasma. Its operations are divided into several key business units: The Bioscience division is dedicated to the research, development, manufacturing, and commercialization of plasma-based medicines and other cutting-edge therapies. These are designed to treat patients suffering from chronic, rare, prevalent, and life-threatening conditions. Their product portfolio includes immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies non-biological pharmaceutical items, medical consumables, clinical nutrition products, intravenous treatments, and various medical devices to healthcare facilities. The Diagnostic division focuses on innovating, producing, and bringing to market diagnostic tools. These tools support the entire healthcare process, from disease prevention and initial screening to definitive diagnosis, prognosis, and ongoing treatment monitoring for medical professionals. The Bio Supplies division provides essential biological materials used in life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic goods. Grifols' diverse range of products and services are utilized by healthcare providers worldwide for diagnosing and treating a variety of medical conditions, including hemophilia, immune system disorders, and infectious diseases. The company caters to a wide customer base that includes both public and private sector clients, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care institutions, and national health systems. Furthermore, Grifols, S.A. maintains a technological collaboration agreement with Mondragon.

Open Grifols, S.A. (GIFOF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.